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Nonalcoholic fatty liver disease (NAFLD) is prevalent 
in people with the metabolic syndrome and type 2 
diabetes. Evidence is now accumulating that NAFLD is 
associated with obesity and diabetes and may serve as 
a predictor of cardiovascular disease. Although at pres-
ent, treatment of the individual risk factors pertinent to 
NAFLD is advocated, novel therapies are emerging that 
may target steatosis and/or inﬂammation, thus amelio-
rating the overall cardiovascular disease risk. Long-term 
outcome studies need to establish whether treatment of 
NAFLD (and in particular which therapy) will affect the 
long-term outcome.
Introduction
In the past decade, nonalcoholic fatty liver disease 
(NAFLD) has gained much interest. NAFLD, which is 
characterized by a wide spectrum of liver disease rang-
ing from liver steatosis to the more severe nonalcoholic 
steatohepatitis (NASH), resembles alcohol-induced liver 
disease. By definition, NAFLD develops in subjects who 
are not heavy alcohol consumers and who have negative 
tests for viral and autoimmune liver diseases. It usually 
has a benign clinical course, but it may progress to NASH, 
fibrosis, cirrhosis, and rarely to hepatocellular carcinoma 
[1,2]. The term NASH was introduced by Ludwig et al. [3] 
in 1980, who reported 20 moderately obese patients with 
liver biopsy changes resembling alcohol-induced hepati-
tis, although none of these patients reported a history of 
alcohol abuse. In recent years, NAFLD has gained appre-
ciation as a pathogenic factor of insulin resistance and type 
2 diabetes mellitus (T2DM). Furthermore, several studies 
showed an association between NAFLD and features of the 
metabolic syndrome, including dyslipidemia and (visceral) 
obesity, stressing the association with insulin resistance 
as an important feature of NAFLD. Currently, NAFLD is 
considered by some authors to be the hepatic component of 
the metabolic syndrome [4,5] and evidence is accumulat-
ing that patients with NAFLD have an increased risk for 
developing cardiovascular disease (CVD).
Epidemiology of NAFLD
NAFLD is a common condition and may be the most preva-
lent liver disorder; however, the true incidence and prevalence 
in the general population are not known. To date, the 
prevalence of NAFLD has been estimated in selected patient 
populations or in studies that are to some extent popula-
tion based. In the NHANES III (third National Health and 
Nutrition Examination Survey), a population-based sample 
of over 15,000 subjects, the prevalence using abnormal 
(ie, above the upper limit of “normal”) values of alanine 
aminotransferase (ALT) and/or aspartate aminotransferase 
(AST) as markers of NAFLD was estimated to be 7.8%, of 
which 31% had an identifiable cause, which would yield a 
prevalence of NAFLD of 5.4%. However, the reported prev-
alences are heavily dependent on the chosen cutoff points for 
ALT. A study in Northern Italy using ultrasound identified 
fatty liver in 16% of lean nondrinkers and a prevalence of 
76% in obese nondrinkers [6]. An ultrasound screening study 
in a Japanese general population found a prevalence of 12%; 
however, this study did not exclude heavy drinkers, which 
might have overestimated the prevalence of NAFLD [7]. 
Overall, in the general population, the estimates of NAFLD 
range between 3% to 36%, but with most estimates in the 
lower range. In obese patients and in patients with T2DM, 
the prevalence of NAFLD is much higher and may be up to 
90% [8]. However, comparisons of the reported prevalences 
of NAFLD are largely hampered by the use of different defi-
nitions in greatly differing study populations.
Diagnosis of NAFLD
The majority of patients with NAFLD are asymptomatic, 
but some may complain of fatigue and right upper quadrant 
abdominal fullness or even pain. Laboratory analyses per-
formed in patients with complaints or at health checkups 
show moderately elevated levels of ALT and AST, with an 
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AST-to-ALT ratio usually less than 1. The other enzymes, 
H-glutamyl transferase and alkaline phosphatase, may also 
be elevated. Noninvasive imaging techniques, such as ultra-
sonography and CT, may assist in the diagnosis of fatty liver 
disease. Ultrasound examination of the liver has a sensitiv-
ity and specificity of 80% to 90% in identifying fatty liver 
infiltrates, compared with liver biopsies [9]. CT has a higher 
sensitivity, but is more expensive than ultrasonography. In 
contrast to liver biopsies, these imaging techniques cannot 
distinguish steatosis from steatohepatitis. However, the role 
of liver biopsy, which is regarded as the “gold standard,” is 
controversial because of the elaborate and invasive nature 
and associated risks of this technique, and the general 
benign clinical course of NAFLD. In addition, no consensus 
exists on the standardization of diagnostic criteria based on 
liver histology, although a number of scoring systems for 
NAFLD have been introduced [10••]. Only patients who are 
suspected to have an advanced stage of the disease, based on 
clinical judgment, ultrasound, and biochemistry, should be 
considered for liver biopsy. For example, in a patient with 
T2DM, morbid obesity, advanced age, or an AST-to-ALT-
ratio greater that 1, a biopsy may be considered. [11]. The 
American Gastroenterological Association (AGA) recom-
mends that in patients with suspected NAFLD a detailed 
history on alcohol intake should be taken to exclude the 
possibility of alcohol-induced hepatic steatosis and steato-
hepatitis. The initial laboratory assessment should include 
ALT, AST, alkaline phosphatase, serum bilirubin and albu-
min levels, prothrombin time, and serologic tests for viral 
hepatitis infection. An imaging study should be performed 
when other causes of liver disease have been excluded. The 
decision to perform a liver biopsy may depend on the specific 
clinical circumstances of individual patients in addition to 
the risks and benefits of performing a liver biopsy and should 
always, as stated by the AGA, include the patient in the deci-
sion making process [12].
In epidemiologic studies, ALT has been used as a 
marker for liver fat accumulation. Studies assessing the 
specificity and sensitivity of ALT as a marker of NAFLD 
are limited [13,14] and applying the laboratory defined cut-
off value (ie, upper limit of the laboratory reference range) 
may underestimate the prevalence of NAFLD [14]. Prati et 
al. [15] have suggested new cutoff values for ALT in order 
to facilitate the identification of subjects with NAFLD. 
However, because cutoff values largely depend on the assay 
used, this proposal has been questioned [16]. One study 
has assessed the correlation of ALT with proton spectros-
copy MRI; it found a modest, but significant correlation 
(r = 0.5) [17]. As is the case for clinical diagnosis, a detailed 
history of alcohol intake is mandatory to exclude those 
patients with ALT elevation caused by alcohol abuse and 
to address alcohol intake as a possible confounder or effect 
modifier. Viral and autoimmune liver disease and hepato-
toxic medication should be considered as well. With these 
limitations in mind, ALT may be an acceptable marker for 
hepatic steatosis in epidemiologic studies.
NAFLD in Relation to the Metabolic 
Syndrome and Type 2 Diabetes
The putative role of the liver in the pathogenesis of T2DM 
has gained much interest. Several cross-sectional studies 
have demonstrated that NAFLD is related to features of the 
metabolic syndrome and T2DM [18–20]. In the analysis of 
the NHANES III, up to 31% of the elevated aminotransfer-
ase activity could be explained by high alcohol consumption, 
hepatitis B or C infection, and/or high transferrin saturation, 
whereas in the remaining 69%, the elevated ALT activity 
was significantly associated with higher body mass index 
(BMI), waist circumference, triglycerides, fasting insulin, 
and lower high-density lipoprotein (HDL) cholesterol [18]. 
Several studies have addressed the prospective relation of 
ALT and the metabolic syndrome and T2DM. Nakanishi 
et al. [21] found that ALT was associated with future risk 
of metabolic syndrome in middle-aged Japanese men, but 
used BMI instead of waist circumference to define the meta-
bolic syndrome. Hanley et al. [22] studied the relationship 
of four different liver enzymes (including ALT) with the 
development of the metabolic syndrome in a multi-ethnic 
cohort. They demonstrated that ALT was associated with an 
increased risk of incident metabolic syndrome. In the Hoorn 
Study, a population-based cohort study among elderly white 
men and women, we found that ALT was associated with 
the development of the metabolic syndrome after 6 years of 
follow-up [23].
In patients with T2DM, elevated serum ALT enzyme 
activity is more frequently observed than in the general 
population [24,25]. In addition, some [26–30], but not all 
studies [21,31–33] have demonstrated independent and sig-
nificant associations of ALT with future T2DM. In 1988, 
Ohlson et al. [26] demonstrated that baseline ALT was a 
predictor of incident T2DM after 13.5 years of follow-up in 
a cohort of 766 Swedish men, with a significant fourfold risk 
for those men in the upper quintile compared with those in 
the lower quintile. In the final multivariate model, ALT was 
a predictor of incident T2DM in 451 Pima Indians after an 
average of 6.9 years, after adjustment for fasting blood glu-
cose levels, BMI, bilirubin, systolic blood pressure, uric acid, 
and a family history of diabetes [26]. Vozarova et al. [27] 
found that higher ALT (upper compared with lower decile) 
was a significant and independent predictor of T2DM with 
a twofold increase risk, after adjustment for age, sex, body 
fat, insulin sensitivity, and acute insulin response. Other 
studies, mainly performed in men, confirmed these earlier 
studies [28,29], whereas recent population-based studies 
could not demonstrate independent associations of ALT 
and future risk of T2DM [32,33]. The observed association 
between ALT and incident T2DM in the mentioned stud-
ies may be explained by the fact that they were performed 
in high-risk populations, which may not be representative 
of the general population. Overall, these studies show that 
patients with NAFLD are at increased risk for T2DM and 
the metabolic syndrome, suggesting that the increased CVD 
risk may be mediated via components of the metabolic 
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syndrome and T2DM. Because the pathophysiology linking 
NAFLD with either the metabolic syndrome and/or diabetes 
has not been clarified, it is difficult to make the distinc-
tion between confounding and mediating variables in the 
epidemiologic analyses.
NAFLD and Increased CVD Risk
Several cross-sectional studies have demonstrated an 
increase in carotid artery intima-media thickness (CIMT) 
in patients with NAFLD [34–36]. However, in these stud-
ies diagnosis of NAFLD was based on evaluation of liver 
enzymes or on ultrasound evaluation but not confirmed 
by liver biopsy, which is regarded as the “gold standard” 
in the diagnosis of NAFLD [10••]. In a recent study, 
Targher et al. [37••] demonstrated that patients with 
biopsy-proven NAFLD have a significantly higher CIMT 
compared with age-, sex-, and BMI-matched healthy 
control subjects. Moreover, they demonstrated that the 
histologically assessed NAFLD predicted CIMT, indepen-
dent of classical risk factors, including insulin resistance 
and components of the metabolic syndrome.
Previously, in patients with well-controlled T2DM, 
we have shown that slightly elevated ALT, as a surro-
gate marker of NAFLD, is associated with a decreased 
brachial artery flow-mediated vasodilatation and an 
impaired whole-body insulin sensitivity [38]. In line with 
the observation in patients with T2DM, it was shown 
that nondiabetic patients with NAFLD have a decreased 
brachial artery flow-mediated vasodilatation compared 
with matched healthy control subjects, independent of 
other risk factors, including insulin resistance and com-
ponents of the metabolic syndrome [39]. Ioannou et al. 
[40] studied the association of ALT and the calculated 
10-year risk of coronary heart disease as estimated with 
the Framingham risk score. Subjects with elevated ALT 
values had a significantly higher Framingham risk score 
compared to those with normal ALT values, indicating a 
higher CVD risk in patients with NAFLD [40].
Only a limited number of studies have addressed the 
prospective relation of ALT with CVD and mortality. 
In the Hoorn Study, a population-based cohort of white 
men and women aged 50 to 75 years, we studied the asso-
ciation of ALT at baseline with all-cause mortality and 
incident cardiovascular and coronary heart disease events 
[41] and found a significant association of ALT with 
coronary heart disease after adjustment for components 
of the metabolic syndrome and traditional CVD risk fac-
tors. We found no independent associations of ALT with 
CVD events and all-cause mortality. The latter result was 
in line with a previous study by Arndt et al. [42], who 
studied the association of ALT with all-cause mortality in 
8043 male construction workers and found no significant 
association. In contrast, a recent study by Nakamura et 
al. [43] found a positive association of ALT with all-cause 
mortality in Japanese men and women, but only for those 
with a BMI below the median (22.7 kg/m2).
Mechanisms Linking NAFLD to Increased 
CVD Risk
The increased CVD risk associated with NAFLD might 
be explained by the close relation of NAFLD with com-
ponents of the metabolic syndrome and T2DM; however, 
recent studies support the notion that NAFLD in itself 
might contribute to the increased CVD risk (Table 1). 
However, the mechanisms for this putative relationship 
are not clear. Several probably highly interrelated factors 
contribute to the enhanced risk of diabetes and metabolic 
syndrome in persons with NAFLD (Fig. 1).
Oxidative stress and inflammation
Hepatic steatosis mediated by insulin resistance is required for 
subsequent events (of which oxidative stress is an important 
contributor) that lead to liver injury and disease progression 
[44]. However, the underlying factors that promote disease 
progression to cirrhosis are not understood. Enhanced 
free fatty acid oxidation increases the formation of oxygen 
Table 1. Cardiometabolic risk determinants or surrogate end-point markers associated with NAFLD and NASH 
Study CVD risk determinants 
Nakanishi et al. [21], Hanley et al. [22], and Schindhelm et al. [23] Metabolic syndrome
Ohlson et al. [26], Vozarova et al. [27], Sattar et al. [28], Hanley et al. [29], 
and Wannamethee et al. [30]
Type 2 diabetes mellitus
Brea et al. [34] and Targher et al. [35,36] Carotid intima-media thickness 
Schindhelm et al. [38] and Villanova et al. [39] Endothelial dysfunction 
Kerner et al. [45] and Targher et al. [47] Oxidative stress and inﬂammation
Pagano et al. [48] and Targher et al. [49] Adiponectin
Pagano et al. [52] Resistin 
Cassader et al. [54] and Musso et al. [55] Postprandial hypertriglyceridemia
Su et al. [56] Postprandial hyperglycemia
CVD—cardiovascular disease; NAFLD—nonalcoholic fatty liver disease; NASH—nonalcoholic steatohepatitis.
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radicals, in turn leading to lipid peroxidation, mitochondrial 
dysfunction, and cell damage with subsequent release of 
cytokines, including tumor necrosis factor-B, interleukin-6, 
and C-reactive protein (CRP). Kerner et al. [45] found an 
association of ALT with CRP. In contrast, Haukeland et al. 
[46] studied the role of systemic inflammation in individu-
als with NAFLD and NASH compared with healthy control 
subjects. It was demonstrated that interleukin-6, but not 
CRP, after adjustment for BMI, age, and sex, was elevated in 
NAFLD compared with control subjects and tumor necrosis 
factor-B was higher in NASH compared with NAFLD [46]. 
Of interest, a study by Targher et al. [47] demonstrated that 
CRP was elevated in individuals with NAFLD, but this asso-
ciation was largely explained by the amount of visceral fat.
Adiponectin, leptin, and resistin 
Decreased adiponectin levels may represent another 
mechanism linking NAFLD to CVD. Patients with 
NAFLD have lower levels of adiponectin compared with 
healthy control subjects, independent of components of the 
metabolic syndrome [46,48,49]. This observation may be 
relevant because some studies have shown that lower levels 
of adiponectin are associated with CVD [50]. Leptin is a 
cytokine hormone mainly produced by adipocytes, which 
regulates food intake and fat metabolism through actions 
on the central nervous system. It has been suggested that 
leptin may act as one of the regulators in progression of 
NAFLD to NASH by upregulation of transforming growth 
factor-C [51]. However, a recent study found no association 
of leptin with liver disease severity [52]. Resistin is a protein 
expressed in adipose tissue and related to insulin resistance 
in mice [53]. Recently, a relationship of resistin, NAFLD, 
and NASH was demonstrated in humans, with higher 
plasma resistin levels in individuals with NASH [52].
Postprandial dysmetabolism
Studies comparing the postprandial response of triglycer-
ides and free fatty acids to a fat-rich meal in nondiabetic 
subjects with biopsy-proven NASH to control subjects 
showed that patients with NASH had significantly higher 
postprandial triglyceride levels than healthy control sub-
jects [54,55]. Another study demonstrated that patients 
with ultrasound-diagnosed NAFLD with an abnormal 
ALT and/or AST had higher glucose levels after a 75-g 
oral glucose tolerance test than those with normal ALT 
and/or AST [56]. Toledo et al. [57••] observed that in 
obese patients with T2DM, increased hepatic steatosis, 
as quantified by CT scanning, was positively correlated 
with serum triglycerides and inversely with HDL cho-
lesterol. No difference in low-density lipoprotein (LDL) 
cholesterol and apolipoprotein B100 was observed rela-
tive to the degree of hepatic steatosis. However, the LDL 
particle size was smaller in the group with severe hepatic 
steatosis. These observations indicate that hepatic ste-
atosis may contribute to the increased CVD risk in these 
patients by increasing triglyceride enrichment of very low 
density lipoprotein (VLDL) particles, lowering HDL cho-
lesterol and by increasing small, dense LDL particles. The 
relationship of hepatic steatosis with serum triglycerides 
was stronger in subjects with a minor degree of hepatic 
steatosis and weaker in those with a more severe degree 
of hepatic steatosis, which may, as the authors suggested, 
indicate that that the incorporation of triglycerides into 
VLDL may have a limited capacity [57••].
Management of NAFLD-associated 
Cardiometabolic Abnormalities or NAFLD?
Lifestyle interventions, including diets and exercise, 
leading to weight loss and concomitant improvement of 
the CVD risk profile, have been shown to lower liver fat 
content [58,59]. These interventions may improve insulin 
sensitivity and/or reduce oxidative stress, both important 
pathophysiologic factors in the pathogenesis of NAFLD 
and CVD. Although these lifestyle interventions seem 

































Figure 1. Overview of the mecha-
nisms—increased uptake of free fatty acids 
(FFAs) by the liver, an increase in de novo 
lipogenesis, impaired C oxidation caused 
by mitochondrial dysfunction, and an insuf-
ﬁcient assembly and secretion of very low 
density lipoproteins (VLDLs)—involved in 
the development of nonalcoholic fatty liver 
disease (NAFLD) and the contribution of 
NAFLD to cardiovascular risk. ALT—alanine 
aminotransferase; CRP—C-reactive protein; 
TG—triglycerides.
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been established and might not be sufficient in patients 
with multiple cardiometabolic risk factors, such as per-
sons with the metabolic syndrome and/or T2DM.
Several pharmacologic agents, including metfor-
min and peroxisome proliferator-activated receptor-H
(PPAR-H) agonists, have been used in the treatment of 
NAFLD. An open-labeled trial of 20 mg/kg of metformin 
for 1 year demonstrated only a transient improvement 
of liver enzymes [60]. Tiikkainen et al. [61] compared 
the effect of 2 g of metformin to 8 mg of the PPAR-H
agonist rosiglitazone on liver fat content and hepatic insu-
lin sensitivity in a 16-week double-blind randomized trial 
in 20 subjects. They found that rosiglitazone decreased 
liver fat by 51%, whereas no significant decrease was 
observed in the metformin-treated subjects. In contrast, 
Bugianesi et al. [62] found that 2 g of metformin led to 
more ALT normalization (ie, below the reference range) 
than either vitamin E or diet-induced weight reduction in 
55 subjects in a 12-month open-labeled randomized trial. 
Metformin induced a decrease of 50% in liver fat and a 
decrease of inflammation and necrosis, using paired liver 
biopsies [62]. Unfortunately, in this study no paired biop-
sies were performed in the subjects who were randomized 
to vitamin E or the weight reduction intervention; thus, 
the level of liver histology improvement in the treatment 
group could not be compared with the effect in the control 
group. A recently reported 6-month placebo-controlled 
trial of diet combined with pioglitazone compared to 
diet with placebo in 55 patients with liver biopsy–proven 
NAFLD demonstrated a significant decrease in ALT and 
hepatic fat content (by 54%) and a significant increase in 
hepatic insulin sensitivity [63••].
More recently introduced pharmacologic agents, 
including glucagon-like peptide-1 (GLP-1), receptor 
agonists, incretin-mimetics known to promote insulin 
production and secretion, and rimonabant, a cannabinoid 
receptor-1 (CB1) antagonist, may be of therapeutic value 
in the treatment of NAFLD and NASH. In ob/ob mice, 
Ding et al. [64] demonstrated that 60 days of adminis-
tration of a GLP-1 receptor agonist reduced hepatic 
steatosis. This reduction in hepatic fat content was not 
only related to a decrease in body weight, but also to a 
decrease in regulatory genes of fatty acid synthesis [65]. 
Recently, Tushuizen et al. [65] reported on a 59-year-old 
male with T2DM treated with a GLP-1 receptor agonist 
for 44 weeks. They found a significant decrease in liver 
fat measured by liver spectroscopy, suggesting that GLP-1 
receptor agonists may be a potential treatment modality 
in patients with NAFLD. However, more studies assessing 
the effect of GLP-1 receptor agonists on hepatic steatosis 
are needed to confirm these results and assess the applica-
bility of these agents for the treatment of hepatic steatosis 
[65]. Rimonabant has been shown to be effective in weight 
reduction and improvement of lipid profile [66]; however, 
the effect of rimonabant on lowering of liver fat content 
and improvement of liver histology beyond weight loss in 
patients with NAFLD needs to be evaluated. Of interest, 
a recent study demonstrated that treatment with the CB1 
receptor antagonist SR14716A in mice inhibited fibrosis 
in liver injury models [67], suggesting that treatment with 
a CB1 receptor antagonist may be a future therapeutic 
modality in NAFLD and NASH.
Conclusions
Evidence is now accumulating that NAFLD is associated 
with cardiovascular risk factors, with markers of sub-
clinical atherosclerosis, and with overt CVD events. This 
increased risk for CVD necessitates the evaluation and 
treatment of these patients. Long-term outcome studies 
need to establish the benefit of treatment of NAFLD on 
the reduction and prevention of diabetes and CVD risk.
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